戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1 entify predictors for discontinuation due to inefficacy and adverse events.
2 cent of patients (n = 5) had treatment-related grade 3 or 4 adverse events.
3 least one dose of study drug in terms of treatment-emergent adverse events.
4 ID-19, and safety, as measured by the occurrence of serious adverse events.
5 ost frequently occurring, yet preventable hospital-acquired adverse events.
6 re were no significant between-group differences in serious adverse events.
7 ys of patient's ICU discharge date to identify and classify adverse events.
8 als with major decreases in LOS had a higher risk of severe adverse events [1.22 (1.11-1.34)] and death [1.17 (1.04-1.32)
9      At a median follow-up of 6.6 years, there were 8 major adverse events: 6 relapses, 1 treatment-related death (from s
10                                                     Serious adverse events (AEs) occurred in 10% of imipenem/relebactam a
11                 Detailed study of ophthalmic immune-related adverse events (AEs), including determination of incidence an
12 t-reported local reactions (LRs) and systemic events (SEs), adverse events (AEs), serious AEs, newly diagnosed chronic me
13                                       Pembrolizumab-related adverse events affected 71% of the patients, and 4 (7%) were
14 ntermediate-risk PE, there were no deaths or device-related adverse events and a significant reduction in right ventricul
15 lular carcinoma (HCC) because of the potential for profound adverse events and large variations in survival outcome.
16 Six subjects tolerated a total of 17 FUS treatments with no adverse events and neither cognitive nor neurological worseni
17                                  There was no difference in adverse events between randomised groups.
18 served 6 of 28 patients (21%) with grade >=3 immune-related adverse events, consisting of asymptomatic laboratory abnorma
19 al toxicity tables that include the incidence of high-grade adverse events, defined by the Common Terminology Criteria fo
20                                Proportions of patients with adverse events did not differ significantly among groups.
21                                               Incidences of adverse events, drug continuation, implantable cardioverter d
22 .17-24.65), any adverse event (OR 1.55, 95% CI: 1.03-2.33), adverse events due to decreased appetite (OR 3.56, 95% CI: 1.
23 me components, biological and pharmacokinetic measures, and adverse events graded 2 or higher.
24 t clinical efficacy, there is also the potential for severe adverse events, including cytokine release syndrome (CRS).
25                                           Treatment-related adverse events (mainly mild or moderate local reactions) were
26  protocols and/or trial registration, and poor reporting of adverse events, methods of sequence generation and allocation
27                                            Nonfatal serious adverse events occurred in 12/72 (16.7%) in the oral group an
28                            The incidence of dental and skin adverse events of special interest was higher with the 10-mg
29 ts, do not provide information on the time profile of these adverse events or reflect the continuous, lower grade symptom
30 rawal for any reason (OR 2.61, 95% CI: 1.38-4.96) or due to adverse events (OR 2.65, 95% CI: 1.04-6.80), any serious adve
31 al selinexor induced durable responses and had a manageable adverse events profile in patients with relapsed or refractor
32 d on median pure tone averages (PTA), and procedure-related adverse events rated by the Common Terminology Criteria for A
33 serious adverse event (OR 2.30, 95% CI: 1.18-4.48), serious adverse events related to abnormal liver function tests (OR 1
34                                                        Most adverse events resulted only in symptoms (77%) and 36% were j
35 ment (TPVR) is associated with a risk of procedural serious adverse events (SAE) and exposure to ionizing radiation.
36 f-treatment outcomes, culture-conversion rates, and serious adverse events (SAEs) during treatment.
37 to immunotherapy and simultaneously identify immune-related adverse events, there are several challenges in interpreting
38       The percentage of participants with local or systemic adverse events was similar in the two groups.
39               By a stepwise method to capture all available adverse events, we first extracted data on myelodysplastic sy
40                    Progression-free survival (PFS), OS, and adverse events were also assessed.
41  contrast sensitivity, endothelial cell count, and possible adverse events were assessed at least 12 months postoperative
42                                                  No serious adverse events were attributed to dihydroartemisinin-piperaqu
43                           All patients had engraftment, and adverse events were consistent with effects of the preparativ
44                                       All treatment-related adverse events were mild or moderate in severity and similar
45                                                     Serious adverse events were more common with systematic treatment.
46 99m)Tc-PHC-102 was well tolerated and no study drug-related adverse events were recorded.
47                                               Eight serious adverse events were reported with capsular release and two wi
48                                   Serious procedure-related adverse events were uncommon.
49                                    There were no unexpected adverse events with (177)Lu-PSMA retreatment.
50                      There were decreased Optimizer-related adverse events with the 2-lead system compared with the 3-lea